NADAC acquisition cost data for SAVAYSA 60 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65597020305 | $12.46 | 2022-07-20 | Rx |
| 65597020330 | $12.46 | 2022-07-20 | Rx |
| 65597020390 | $12.46 | 2022-07-20 | Rx |
| 65597020305 | $12.46 | 2022-07-20 | Rx |
| 65597020330 | $12.46 | 2022-07-20 | Rx |
| 65597020390 | $12.46 | 2022-07-20 | Rx |
| 65597020305 | $12.46 | 2022-07-20 | Rx |
| 65597020330 | $12.46 | 2022-07-20 | Rx |
| 65597020390 | $12.46 | 2022-07-20 | Rx |
| 65597020305 | $12.46 | 2022-07-20 | Rx |
Generic: Edoxaban Tosylate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $8.4M | 16,065 | 3,135 | $12.05 |
| 2020 | $7.8M | 13,286 | 2,452 | $12.87 |
| 2021 | $6.7M | 10,833 | 2,089 | $13.09 |
| 2022 | $5.8M | 9,423 | 1,786 | $13.21 |
| 2023 | $5.3M | 8,293 | 1,610 | $13.68 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $739.1K | 1,113 | 222 |
| New York | $547.4K | 882 | 164 |
| Florida | $309.3K | 457 | 99 |
| North Carolina | $266.1K | 409 | 80 |
| Texas | $257.7K | 375 | 87 |
| Pennsylvania | $234.3K | 432 | 73 |
| Massachusetts | $204.6K | 294 | 68 |
| New Jersey | $204.0K | 265 | 60 |
| Ohio | $183.6K | 288 | 60 |
| Michigan | $180.3K | 272 | 56 |
| Illinois | $159.9K | 239 | 53 |
| Arizona | $147.7K | 173 | 42 |
| Washington | $146.8K | 254 | 50 |
| Connecticut | $119.7K | 187 | 30 |
| Indiana | $117.8K | 179 | 42 |
| Virginia | $115.3K | 189 | 39 |
| Maryland | $113.8K | 155 | 36 |
| Oregon | $101.7K | 140 | 32 |
| Colorado | $94.0K | 126 | 30 |
| Tennessee | $93.3K | 139 | 30 |
| Georgia | $82.4K | 141 | 25 |
| Missouri | $82.3K | 121 | 27 |
| Utah | $80.8K | 124 | 28 |
| South Carolina | $75.8K | 153 | 19 |
| Minnesota | $75.4K | 121 | 25 |
| Oklahoma | $58.3K | 96 | 18 |
| Louisiana | $57.8K | 112 | 21 |
| Alabama | $51.3K | 80 | 16 |
| Montana | $48.5K | 96 | 12 |
| Nebraska | $42.0K | 85 | 11 |
| Kentucky | $39.2K | 63 | 13 |
| Maine | $38.3K | 74 | 13 |
| Iowa | $38.0K | 56 | 11 |
| Kansas | $31.0K | 61 | 11 |
| Puerto Rico | $26.2K | 39 | N/A |
| Idaho | $19.2K | 40 | N/A |
| Mississippi | $18.3K | 31 | N/A |
| Wisconsin | $17.9K | 41 | N/A |
| Rhode Island | $15.7K | 18 | N/A |
| Vermont | $13.9K | 16 | N/A |
| Arkansas | $13.4K | 33 | N/A |
| Nevada | $12.5K | 14 | N/A |
| District of Columbia | $12.2K | 16 | N/A |
| West Virginia | $9.2K | 16 | N/A |
| Delaware | $5.2K | 15 | N/A |
| North Dakota | $5.0K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.